Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling

Pal, Sumanta K.; Ali, Siraj M.; Yakirevich, Evgeny; Geynisman, Daniel M.; Karam, Jose A.; Elvin, Julia A.; Frampton, Garrett M.; Huang, Xuan; Lin, Douglas I.; Rosenzweig, Mark R.; Lipson, Doron; Stephens, Philip J.; Ross, Jeffrey S.; Miller, Vincent A.; Agarwal, Neeraj; Shuch, Brian; Choueiri, Toni K.; Chung, Jon

doi:10.1016/j.eururo.2017.05.033

Cited by 94 publications

(48 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Somatic mutation of ARID1A has been reported in several human cancer tissues, including ovarian clear cell carcinoma (57%) (16), uterine endometrioid carcinoma (40%) (17), and gastric carcinoma (30%) (18). Although alterations in ARID1A gene expression and protein level have been reported in some cases of RCC (10, 13), the role for ARID1A down‐regulation in RCC remained unclear and underinvestigated. The present study thus aimed to define mechanistic roles of ARID1A down‐regulation by small interfering RNA (siRNA) against ARID1A (siARID1A) in carcinogenesis features of renal cells, including cell proliferation, cell death, cell cycle distribution, spindle index, epithelial‐mesenchymal transition (EMT), migratory activity, nuclear size, self‐aggregated spheroid formation, invasion capability, and chemoresistance.…”

mentioning

confidence: 99%

“…ARID1A is a key component of the Switch/sucrose nonfermentable (SWI/SNF) complex (5), which is an ATP dependent-chromatin remodeling complex that plays crucial roles in regulation of many cellular processes, including gene expression, cell proliferation and DNA repair (6). Several lines of evidence have reported the role for this complex in carcinogenesis (7), and an altered expression of genes encoding protein subunits of this complex has been found in various cancers, including protein polybromo-1 (PBRM1), SWI/ SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1), and ARID1A in RCC (8)(9)(10). In addition to genes, alterations in abundant levels of proteins within the SWI/SNF complex (i.e., integrase interactor 1, transcription factor BRG1, and ARID1A) have been also reported in RCC (11)(12)(13).…”

mentioning

confidence: 99%

See 1 more Smart Citation

ARID1A knockdown triggers epithelial‐mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma

et al. 2019

View full text Add to dashboard Cite

Down‐regulation/mutation of AT‐rich interactive domain 1A (ARID1A), a novel tumor suppressor gene, has been reported in various cancers. Nevertheless, its role in renal cell carcinoma (RCC) remained unclear and underinvestigated. We thus evaluated carcinogenesis effects of ARID1A knockdown in nonmalignant Madin‐Darby canine kidney (MDCK) renal cells using small interfering RNA (siRNA) against ARID1A (siARID1A). The siARID1A‐transfected cells had decreased cell death, increased cell proliferation, and cell cycle shift (from G0/G1 to G2/M) compared with those transfected with controlled siRNA (siControl). Additionally, the siARID1A‐transfected cells exhibited epithelial‐mesenchymal transition (EMT) shown by greater spindle index, increased mesenchymal markers (fibronectin/vimentin), and decreased epithelial markers (E‐cadherin/zonula occludens‐1). Moreover, the siARID1A‐transfected cells had increases in migratory activity, nuclear size, self‐aggregated multicellular spheroid size, invasion capability, chemoresistance (to docetaxel), Snail family transcriptional repressor 1 expression, and TGF‐β1 secretion. All of these siARID1A‐knockdown effects on the carcinogenic features were reproducible in malignant RCC (786‐O) cells, which exhibited a higher degree of carcinogenic phenotypes compared with the nonmalignant MDCK cells. Finally, immunohistochemistry showed obvious decrease in ARID1A protein expression in human RCC tissues (n = 23) compared with adjacent normal renal tissues (n = 23). These data indicate that ARID1A down‐regulation triggers EMT and carcinogenesis features of renal cells in vitro, and its role in RCC could be proven in human tissues.—Somsuan, K., Peerapen, P., Boonmark, W., Plumworasawat, S., Samol, R., Sakulsak, N., Thongboonkerd, V. ARID1A knockdown triggers epithelial‐mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma. FASEB J. 33, 12226‐12239 (2019). http://www.fasebj.org

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

ARID1A knockdown triggers epithelial‐mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…p1RCC is typically smaller, lower grade, more indolent, and less metastatic than p2RCC [55]. Sporadic p1RCC is associated with MET gene alteration, whereas sporadic p2RCC is characterized by CDKN2A silencing, SETD2 mutations, NF2 mutations, CUL3 mutations, TERT promoter mutations, increased expression of the NRF2-antioxidant pathway, and gains of chromosomes 7, 12, 16, and 17 [9,[56][57][58][59][60]. Hereditary p1RCC is characterized by bilateral, multifocal tumors and germline MET activation mutations [61,62].…”

Section: Papillary Cell Rccmentioning

confidence: 99%

Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan‐omics precision

Hsieh

Cao

et al. 2018

The Journal of Pathology

104

View full text Add to dashboard Cite

Over the past 20 years, classifications of kidney cancer have undergone major revisions based on morphological refinements and molecular characterizations. The 2016 WHO classification of renal tumors recognizes more than ten different renal cell carcinoma (RCC) subtypes. Furthermore, the marked inter-and intra-tumor heterogeneity of RCC is now well appreciated. Nevertheless, contemporary multi-omics studies of RCC, encompassing genomics, transcriptomics, proteomics, and metabolomics, not only highlight apparent diversity but also showcase and underline commonality. Here, we wish to provide an integrated perspective concerning the future 'functional' classification of renal cancer by bridging gaps among morphology, biology, multi-omics, and therapeutics. This review focuses on recent progress and elaborates the potential value of contemporary pan-omics approaches with a special emphasis on cancer genomics unveiled through next-generation sequencing technology, and how an integrated multi-omics approach might impact precision-based personalized kidney cancer care in the near future.

show abstract

“…Papillary renal cell carcinoma (PRCC), accounting for ∼15% of kidney cancers, is the second most common type of renal carcinoma following clear cell renal cell carcinoma [3]. Although comprehensive treatments for PRCC have improved, the overall survival rate (OSR) is still low, especially for advanced or metastatic patients for whom treatment options unfortunately remain limited [4,5] Hence, it is necessary to recognize biomarkers and improve the prognosis of patients with PRCC With the development of microarray and sequencing technology, as well as available open-access databases such as The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), the discovery of biomarkers and identi cation of molecular subtypes have been implemented in several cancers [6,7].…”

Section: Introductionmentioning

confidence: 99%

Construction of a Prognostic Value Model in Papillary Renal Cell Carcinoma by Immune-Related Genes

Wang¹,

Gu²,

Ni³

2020

Preprint

View full text Add to dashboard Cite

Papillary renal cell carcinoma (PRCC) is the second most common type of renal carcinoma following clear cell renal cell carcinoma, and the role of immune-related genes (IRGs) in tumorigenesis and metastasis is evident; its prognostic value in PRCC remains unclear. In this study, we downloaded the gene expression profiles and clinical data of patients with PRCC from The Cancer Genome Atlas (TCGA) database and obtained IRGs from the ImmPort database. A total of 371 differentially expressed IRGs (DEIRGs) were discovered between PRCC and normal kidney tissues. Prognostic DEIRGs (PDEIRGs) were identified by univariate Cox regression analysis. Then, we screened the four most representative PDEIRGs (IL13RA2, CCL19, BIRC5, and INHBE) and used them to construct a risk model to predict the prognosis of patients with PRCC. This model precisely stratified survival outcome and accurately identified mutation burden in PRCC. Thus, our results suggest that these four PDEIRGs are available prognostic predictors for PRCC. They could be used to assess the prognosis and to guide individualized treatments for patients with PRCC.

show abstract

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling

Cited by 94 publications

References 40 publications

ARID1A knockdown triggers epithelial‐mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma

ARID1A knockdown triggers epithelial‐mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma

Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan‐omics precision

Construction of a Prognostic Value Model in Papillary Renal Cell Carcinoma by Immune-Related Genes

Contact Info

Product

Resources

About